Berkeley Lights Announces Opto™ Assure For Early Manufacturability Assessment of Antibody Therapeutics
EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the launch of Opto Assure, a series of assays that provides yield and product quality data at an earlier stage in cell line development. The first of the series enables direct detection of product aggregates, ensuring a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process. With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.
Cell line development has become more challenging with the emergence of complex antibody therapeutic formats. These highly engineered proteins are prone to quality issues including aggregation, by-products, and post-translational modifications, which impact drug manufacturability, shelf life, and safety. Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process. Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.
“We’re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resourcesspent on preventing product failures downstream and ensure a more efficient process,” said John Proctor, Ph.D., SVP of Antibody Therapeutics at Berkeley Lights.
About Berkeley Lights
Forward Looking Statement
The Berkeley Lights Platform and the Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Boosting your UC and Conferencing Revenue